Showing results (1-10 of 160) with videos related to
Sort By:
Pageof 16
Oncology (Williston Park, N.Y.)|July 1, 1997
Recent progress in radioimmunotherapy for cancerR F Meredith, A F LoBuglio, E B SpencerBiotechnic & Histochemistry : Official Publication of the Biological Stain Commission|September 15, 1998
Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapyM N Saleh, A B Tilden, R F Meredith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancerR F Meredith, M B Khazaeli, D J Macey, et al.Cancer Biotherapy & Radiopharmaceuticals|April 1, 1997
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trialsT Liu, R F Meredith, M N Saleh, et al.The Journal of Urology|July 1, 1994
Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomasR B Myers, R F Meredith, J Schlom, et al.Journal of Immunological Methods|January 1, 1978
Phagocytosis of technetium-99m sulfur colloid by human polymorphonuclear leukocytesP K Rustagi, A F LoBuglioVox Sanguinis|January 1, 1986
Measurement of platelet surface-bound IgG by a monoclonal 125I-anti-IgG assayW S Court, A F LoBuglioBlood|August 1, 1981
Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burstC A Koller, A F LoBuglioBlood|June 1, 1980
An oxygen-dependent mechanism of neutrophil-mediated cytotoxicityS J Weiss, A F LoBuglioPageof 16